GSK completes demerger of Haleon

GSK

GSK plc (LON:GSK) has completed the demerger of the Consumer Healthcare business from the GSK Group to form the Haleon Group. The shares of Haleon plc (ticker “LSE: HLN”) will be admitted at 8.00 a.m. today to the Premium Listing segment of the Official List and to trading on the Main Market of the London Stock Exchange.

It is expected that American Depositary Shares representing shares of Haleon plc (ticker: “NYSE: HLN”) will commence “regular-way” trading on the New York Stock Exchange at market open on Friday 22 July 2022. In addition, we expect that Haleon ADSs will begin trading on a “when-issued” basis on the NYSE from market open today up to and including Thursday 21 July 2022. Each Haleon ADS represents two Haleon ordinary shares.

GSK Share Consolidation

At the GSK General Meeting on 6 July 2022, alongside the demerger, GSK shareholders also approved the consolidation of GSK shares (the “GSK Share Consolidation”). The GSK Share Consolidation is expected to take place after the market closes today. It is expected that admission and dealings in the new GSK shares on the LSE will commence at 8.00 a.m. on Tuesday 19 July 2022. GSK will provide an update following the completion of the GSK Share Consolidation at around 7.00 a.m. on Tuesday 19 July 2022.

The ratio for the GSK Share Consolidation cannot be fixed at this time as it will depend on fluctuations in the volume and price of the GSK shares in the period between 8.00 a.m. and 4.30 p.m. today.

As at the time of this announcement, GSK’s issued share capital consists of 5,389,096,045 ordinary shares of 25 pence each (including 304,905,950 ordinary shares held in treasury). Therefore, the total number of voting rights in the Company is 5,084,190,095. If the total number of GSK shares in issue prior to the record time at 8.00 p.m. today is not exactly divisible by the denominator in the consolidation ratio, then shortly before the GSK Share Consolidation, GSK will issue up to 49 ordinary shares to ensure that following the GSK Share Consolidation there are no fractional ordinary shares outstanding.

Further information on and key dates in relation to the proposed demerger of Haleon and the GSK Share Consolidation is set out at the end of this announcement and can also be found in the Circular to Shareholders published on 1 June 2022. The Circular is available on GSK’s website at www.gsk.com/demerger.

Expected Timetable of Principal Events

The times and dates set out in the timetable below and throughout this announcement are indicative only and based on GSK’s current expectations and may be subject to change without further notice.

EventTime and date(1)
Commencement of dealings in Existing GSK Shares (ex entitlement to Haleon Shares) on the LSE8 a.m. on Monday 18 July 2022
Admission and commencement of dealings in Haleon Shares on the LSE8 a.m. on Monday 18 July 2022
CREST accounts credited in respect of Haleon Shares in uncertificated formAs soon as practicable after 8 a.m. on Monday 18 July 2022
GSK Share Consolidation record time–8 p.m. on Monday 18 July 2022
GSK Share Consolidation becomes effectiveAfter 8 p.m. on Monday 18 July 2022
GSK Admission and commencement of dealings in New GSK Shares on the LSE8 a.m. on Tuesday 19 July 2022
CREST accounts credited in respect of New GSK Shares in uncertificated formAs soon as practicable after 8 a.m. on Tuesday 19 July 2022
Commencement of trading in Haleon ADSs on a “when-issued” basis on the NYSE9.30 a.m. New York City time on Monday 18 July 2022
Commencement of “regular-way” trading in Haleon ADSs on the NYSE9.30 a.m. New York City time on Friday 22 July 2022
Admission and commencement of dealings in new GSK ADSs on the NYSE9.30 a.m. New York City time on Friday 22 July 2022
Opening of the GSK ADS issuance and cancellation books (2)8 a.m. New York City time on Monday 25 July 2022
Latest date for despatch of:-     definitive share certificates (where applicable) for New GSK Shares in certificated form to Qualifying Shareholders on the GSK Share Register

By Monday 1 August 2022
–     CSN statements for GSK CSN(3)By Monday 1 August 2022
–     definitive share certificates (where applicable) for Haleon Shares in certificated form to Qualifying Shareholders on the GSK Share Register(4)By Thursday 4 August 2022
–     opening statements for Haleon CSN(3) (4)By Thursday 4 August 2022
Posting of payment advice, CREST accounts credited or payment by electronic payment in respect of fractional entitlements arising from the GSK Share ConsolidationWeek commencing Monday 1 August 2022

Notes

(1)  Unless otherwise indicated, all references to time in this timetable are to UK time.

(2)  The Depositary will suspend the issuance and cancellation of GSK ADSs from Thursday 14 July 2022 until Monday 25 July 2022. This means that during this time, you will not be able to convert your GSK ADSs into GSK Shares, surrender your GSK ADSs and receive underlying GSK Shares, or deposit your GSK Shares and receive GSK ADSs. However, the closing of the issuance and cancellation books does not impact trading, and you may continue to trade your GSK ADSs during this period.

(3)  For CSN Shareholders who have a Shareview Portfolio account, and have not elected for paper statements to be issued to them, the CSN statements will only be made available electronically via their account.

(4)  Subject to the timing of the Haleon Capital Reduction.

Share on:
Find more news, interviews, share price & company profile here for:

    Dekel Agri-Vision AGM to be held on 10 September 2025

    Dekel Agri-Vision will hold its Annual General Meeting on 10 September 2025 in London. The Notice of AGM will be available on the company’s website and sent to shareholders who have requested a physical copy.

    Union Jack Oil confirms spudding of Sark well in Oklahoma

    Union Jack Oil has confirmed that the Sark well in Central Oklahoma has been spudded, with the company holding a 60% interest. The well is operated by Reach Oil and Gas Inc., and follows the recent success of the producing Moccasin well.

    Amaroq reports Q2 2025 progress and maiden gold revenue

    Amaroq Ltd. posted C$3.4 million in maiden revenue from first gold doré sales at its Nalunaq mine, alongside higher mining and processing throughput. The company raised £45 million in an oversubscribed equity placing, advanced work on its West Greenland Hub acquisitions, and brought forward Phase 2 flotation recovery installation, targeting 5koz gold output in 2025.

    Admiral Group Plc delivers record £521m profit in H1 2025

    Admiral Group reported a 69% rise in profit before tax to £521 million for the first half of 2025, with earnings per share up 72% and an interim dividend of 115p.

    Touchstone Exploration Q2 2025 Performance Update

    Touchstone Exploration Inc. recorded average production of 4,399 boe/d in Q2 2025, supported by its acquisition of Shell Trinidad Central Block Limited.

    Great Western Mining highlights key Nevada projects at 2025 AGM

    Executive Chairman Brian Hall outlined progress on the Huntoon Copper Project, Olympic Gold’s Rhyolite Dome, early-stage tungsten prospects, and the near-complete Western Milling joint venture, with multiple drilling campaigns and development milestones planned for 2025.

      Search

      Search